Response to bortezomib of a patient with scleromyxedema refractory to other therapies

Leukemia Research

Volumn 35, Issue 11, 2011, Pages

  Migkou, Magdalini ^a   Gkotzamanidou, Maria ^a   Terpos, Evangelos ^a   Dimopoulos, Meletios A ^a   Kastritis, Efstathios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LAMBDA CHAIN; LENALIDOMIDE; M PROTEIN; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MUCIN;

AGED; ARTHRALGIA; CASE REPORT; CELL PROLIFERATION; DRUG DOSE REDUCTION; DRUG RESPONSE; EAR; ELBOW; FACE; FEVER; FIBROBLAST; HAND DISEASE; HAND EDEMA; HUMAN; HUMAN CELL; HUMAN TISSUE; JOINT MOBILITY; KNEE; LETTER; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NECK; PAPULE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SCLEROMYXEDEMA; SENSORY NEUROPATHY; SKIN BIOPSY; SKIN DISEASE; SKINFOLD THICKNESS; SYMPTOMATOLOGY;

AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PYRAZINES; SALVAGE THERAPY; SCLEROMYXEDEMA; TREATMENT OUTCOME;

EID: 80053935817     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.07.021     Document Type: Letter

References (11)

1. Rongioletti F., Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001, 44:273-281.
2. Dinneen A.M., Dicken C.H. Scleromyxedema. J Am Acad Dermatol 1995, 33:37-43.
3. Heymann W.R., Scleromyxedema J Am Acad Dermatol 2007, 57:890-891.
4. Lacy M.Q., Hogan W.J., Gertz M.A., Dispenzieri A., Rajkumar S.V., Hayman S., et al. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Arch Dermatol 2005, 141:1277-1282.
5. Donato M.L., Feasel A.M., Weber D.M., Prieto V.G., Giralt S.A., Champlin R.E., et al. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood 2006, 107:463-466.
6. Harris R.B., Perry H.O., Kyle R.A., Winkelmann R.K. Treatment of scleromyxedema with melphalan. Arch Dermatol 1979, 115:295-299.
7. Boin F., Hummers L.K. Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am 2008, 34. 199-220, ix.
8. Caradonna S., Jacobe H. Thalidomide as a potential treatment for scleromyxedema. Arch Dermatol 2004, 140:277-280.
9. Cokonis Georgakis C.D., Falasca G., Georgakis A., Heymann W.R. Scleromyxedema. Clin Dermatol 2006, 24:493-497.
10. Ataergin S., Arpaci F., Demiriz M., Ozet A. Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema. Am J Clin Dermatol 2008, 9:271-273.
11. Merlini G., Stone M.J. Dangerous small B-cell clones. Blood 2006, 108:2520-2530.